CME 1 Session – EANM’13

PET and SPECT in Oncology Drug Development

Educational objectives:
  1. To have an overview of drug development in oncology
  2. To learn the necessary basic requirements of imaging evaluation in the field of drug development in oncology
  3. To show the possibilities and limits of PET and SPECT imaging in pre-clinical and clinical drug development in oncology
This continuing education session is directed primarily towards nuclear medicine physicians, who are interested in drug development in oncology.
Despite remarkable progress in our understanding of cancer biology, the identification and characterization of novel therapeutic targets and new drugs need a precise analysis of the oncogenic process and of the therapeutic response. In this setting, PET and SPECT offer the potential to give robust, reliable and well characterised answers to scientific questions in cancer research. In particular, PET and SPECT may show a reduction in tumour cell proliferation and an induction of necrotic or apoptotic cell death. New developments in targeted therapies in oncology drug development require assessment of targeted drug kinetics in a non-invasive manner. Both PET and SPECT can offer these, either by using the radiolabeled drug as radiopharmaceutical or by a surrogate imaging biomarker, like [18F]FDG or [18F]FLT.
The CME will thus give an overview of drug development in oncology for the nuclear medicine physician with a focus on pre-clinical and clinical aspects related to PET and SPECT imaging.

Key Words:
Drug Development, Oncology, PET, SPECT

Extended Abstract Book for download (5 MB)

User action required
If you have the permission to view this publication, please log in.